Answers are grounded in this paper and cite their sources.
The prevention and management of radiation-induced toxicities represents an integral part of modern radiation oncology. The German S3 guideline “Supportive Therapy in Oncological Patients” was originally published in 2016 by the Association of the Scientific Medical Societies in Germany ( Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften , AWMF). Based on the latest evidence, its recommendations were revised most recently in April 2025 [ 1 ]. Existing chapters were reviewed, including those on tumor treatment-induced anemia, antiemesis, the use of granulopoietic growth factors, skin and mucosal toxicities, treatment-induced diarrhea, peripheral neurotoxicity, osseous complications, extravasation management, and supportive treatment in radiation oncology. In addition, the guideline has been expanded to cover emerging aspects such as autoimmune diseases as treatment-related adverse effects, cardiotoxicity, central neurotoxicity, and radiation-induced toxicities affecting the urogenital tract. In the following, we provide a concise overview of the current guideline update and discuss its evidence-based recommendations for clinical practice.
No takes yet. Share an insight, caveat, or question.
Dejonckheere et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: